Search

Your search keyword '"Huws, Dyfed W."' showing total 23 results
Start Over Author "Huws, Dyfed W."
23 results on '"Huws, Dyfed W."'

1. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

Bennett, Damien, Butler, John, Cameron, David A, Chew, Cindy, Crosby, Tom, Filsinger, Brooke, Finley, Christian J, Forster, Katharina, Fung, Sharon, Green, Bo, Gomez-Navas, Elba, Gutierrez, Eric, Han, Jihee, Harrison, Samantha, Lawler, Mark, Little, Alana L, Pantarotto, Jason R, Peacock, Stuart J, Ray-Coquard, Isabelle, Thomson, Catherine S, Warlow, Janet L, Whitfield, Emma, McPhail, Sean, Barclay, Matthew E, Swann, Ruth, Johnson, Shane A, Alvi, Riaz, Barisic, Andriana, Bucher, Oliver, Creighton, Nicola, Denny, Cheryl A, Dewar, Ron A, Donnelly, David W, Dowden, Jeff J, Downie, Laura, Finn, Norah, Gavin, Anna T, Habbous, Steven, Huws, Dyfed W, Kumar, S Eshwar, May, Leon, McClure, Carol A, Morrison, David S, Møller, Bjørn, Musto, Grace, Nilssen, Yngvar, Saint-Jacques, Nathalie, Sarker, Sabuj, Shack, Lorraine, Tian, Xiaoyi, Thomas, Robert JS, Wang, Haiyan, Woods, Ryan R, You, Hui, Zhang, Bin, and Lyratzopoulos, Georgios

Published
2024
Full Text
View/download PDF

2. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

Altman, Alon D, Bennett, Damien, Butler, John, Cameron, David A, Crosby, Tom, Davies, Llion, Dixon, Elijah, Filsinger, Brooke, Forster, Katharina, Fung, Sharon, Gomez Navas, Elba, Guren, Marianne G, Han, Jihee, Hanna, Louise, Harrison, Samantha, Lawler, Mark, Little, Alana L, Mala, Tom, Merrett, Neil, Morrison, David S, Nelson, Gregg, Peacock, Stuart J, Ransom, David T, Ray-Coquard, Isabelle, Warlow, Janet L, Whitfield, Emma, Zalcberg, John R, McPhail, Sean, Barclay, Matthew E, Johnson, Shane A, Swann, Ruth, Alvi, Riaz, Barisic, Andriana, Bucher, Oliver, Creighton, Nicola, Denny, Cheryl A, Dewar, Ron A, Donnelly, David W, Dowden, Jeff J, Downie, Laura, Finn, Norah, Gavin, Anna T, Habbous, Steven, Huws, Dyfed W, May, Leon, McClure, Carol A, Møller, Bjørn, Musto, Grace, Nilssen, Yngvar, Saint-Jacques, Nathalie, Sarker, Sabuj, Shack, Lorraine, Tian, Xiaoyi, Thomas, Robert J S, Thomson, Catherine S, Wang, Haiyan, Woods, Ryan R, You, Hui, and Lyratzopoulos, Georgios

Published
2024
Full Text
View/download PDF

4. Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

Filsinger, Brooke, Forster, Katharina, May, Leon, Morrison, David S, Thomas, A. Ffion, Warlow, Janet L, You, Hui, McPhail, Sean, Swann, Ruth, Johnson, Shane A, Barclay, Matthew E, Abd Elkader, Hazem, Alvi, Riaz, Barisic, Andriana, Bucher, Oliver, Clark, Gavin R C, Creighton, Nicola, Danckert, Bolette, Denny, Cheryl A, Donnelly, David W, Dowden, Jeff J, Finn, Norah, Fox, Colin R, Fung, Sharon, Gavin, Anna T, Gomez Navas, Elba, Habbous, Steven, Han, Jihee, Huws, Dyfed W, Jackson, Christopher G C A, Jensen, Henry, Kaposhi, Bethany, Kumar, S Eshwar, Little, Alana L, Lu, Shuang, McClure, Carol A, Møller, Bjørn, Musto, Grace, Nilssen, Yngvar, Saint-Jacques, Nathalie, Sarker, Sabuj, te Marvelde, Luc, Thomas, Rebecca S, Thomas, Robert J S, Thomson, Catherine S, Woods, Ryan R, Zhang, Bin, and Lyratzopoulos, Georgios

Published
2022
Full Text
View/download PDF

6. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

Author

Arnold, Melina, Rutherford, Mark J, Bardot, Aude, Ferlay, Jacques, Andersson, Therese M-L, Myklebust, Tor Åge, Tervonen, Hanna, Thursfield, Vicky, Ransom, David, Shack, Lorraine, Woods, Ryan R, Turner, Donna, Leonfellner, Suzanne, Ryan, Susan, Saint-Jacques, Nathalie, De, Prithwish, McClure, Carol, Ramanakumar, Agnihotram V, Stuart-Panko, Heather, Engholm, Gerda, Walsh, Paul M, Jackson, Christopher, Vernon, Sally, Morgan, Eileen, Gavin, Anna, Morrison, David S, Huws, Dyfed W, Porter, Geoff, Butler, John, Bryant, Heather, Currow, David C, Hiom, Sara, Parkin, D Max, Sasieni, Peter, Lambert, Paul C, Møller, Bjørn, Soerjomataram, Isabelle, and Bray, Freddie

Published
2019
Full Text
View/download PDF

7. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom

Author

Donnelly, David W., Gavin, Anna, Downing, Amy, Hounsome, Luke, Kearney, Therese, McNair, Emma, Allan, Dawn, Huws, Dyfed W., Wright, Penny, Selby, Peter J., Kind, Paul, Watson, Eila, Wagland, Richard, Wilding, Sarah, Butcher, Hugh, Mottram, Rebecca, Allen, Majorie, McSorley, Oonagh, Sharp, Linda, Mason, Malcolm D., Cross, William R., Catto, James W.F., and Glaser, Adam W.

Published
2019
Full Text
View/download PDF

8. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

McPhail, Sean, primary, Barclay, Matthew E, additional, Johnson, Shane A, additional, Swann, Ruth, additional, Alvi, Riaz, additional, Barisic, Andriana, additional, Bucher, Oliver, additional, Creighton, Nicola, additional, Denny, Cheryl A, additional, Dewar, Ron A, additional, Donnelly, David W, additional, Dowden, Jeff J, additional, Downie, Laura, additional, Finn, Norah, additional, Gavin, Anna T, additional, Habbous, Steven, additional, Huws, Dyfed W, additional, May, Leon, additional, McClure, Carol A, additional, Møller, Bjørn, additional, Musto, Grace, additional, Nilssen, Yngvar, additional, Saint-Jacques, Nathalie, additional, Sarker, Sabuj, additional, Shack, Lorraine, additional, Tian, Xiaoyi, additional, Thomas, Robert J S, additional, Thomson, Catherine S, additional, Wang, Haiyan, additional, Woods, Ryan R, additional, You, Hui, additional, Lyratzopoulos, Georgios, additional, Altman, Alon D, additional, Bennett, Damien, additional, Butler, John, additional, Cameron, David A, additional, Crosby, Tom, additional, Davies, Llion, additional, Dixon, Elijah, additional, Filsinger, Brooke, additional, Forster, Katharina, additional, Fung, Sharon, additional, Gomez Navas, Elba, additional, Guren, Marianne G, additional, Han, Jihee, additional, Hanna, Louise, additional, Harrison, Samantha, additional, Lawler, Mark, additional, Little, Alana L, additional, Mala, Tom, additional, Merrett, Neil, additional, Morrison, David S, additional, Nelson, Gregg, additional, Peacock, Stuart J, additional, Ransom, David T, additional, Ray-Coquard, Isabelle, additional, Warlow, Janet L, additional, Whitfield, Emma, additional, and Zalcberg, John R, additional

Published
2024
Full Text
View/download PDF

9. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

McPhail, Sean, primary, Barclay, Matthew E, additional, Swann, Ruth, additional, Johnson, Shane A, additional, Alvi, Riaz, additional, Barisic, Andriana, additional, Bucher, Oliver, additional, Creighton, Nicola, additional, Denny, Cheryl A, additional, Dewar, Ron A, additional, Donnelly, David W, additional, Dowden, Jeff J, additional, Downie, Laura, additional, Finn, Norah, additional, Gavin, Anna T, additional, Habbous, Steven, additional, Huws, Dyfed W, additional, Kumar, S Eshwar, additional, May, Leon, additional, McClure, Carol A, additional, Morrison, David S, additional, Møller, Bjørn, additional, Musto, Grace, additional, Nilssen, Yngvar, additional, Saint-Jacques, Nathalie, additional, Sarker, Sabuj, additional, Shack, Lorraine, additional, Tian, Xiaoyi, additional, Thomas, Robert JS, additional, Wang, Haiyan, additional, Woods, Ryan R, additional, You, Hui, additional, Zhang, Bin, additional, Lyratzopoulos, Georgios, additional, Bennett, Damien, additional, Butler, John, additional, Cameron, David A, additional, Chew, Cindy, additional, Crosby, Tom, additional, Filsinger, Brooke, additional, Finley, Christian J, additional, Forster, Katharina, additional, Fung, Sharon, additional, Green, Bo, additional, Gomez-Navas, Elba, additional, Gutierrez, Eric, additional, Han, Jihee, additional, Harrison, Samantha, additional, Lawler, Mark, additional, Little, Alana L, additional, Pantarotto, Jason R, additional, Peacock, Stuart J, additional, Ray-Coquard, Isabelle, additional, Thomson, Catherine S, additional, Warlow, Janet L, additional, and Whitfield, Emma, additional

Published
2024
Full Text
View/download PDF

10. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study

Author

Downing, Amy, Wright, Penny, Hounsome, Luke, Selby, Peter, Wilding, Sarah, Watson, Eila, Wagland, Richard, Kind, Paul, Donnelly, David W, Butcher, Hugh, Catto, James W F, Cross, William, Mason, Malcolm, Sharp, Linda, Weller, David, Velikova, Galina, McCaughan, Eilis, Mottram, Rebecca, Allen, Majorie, Kearney, Therese, McSorley, Oonagh, Huws, Dyfed W, Brewster, David H, McNair, Emma, Gavin, Anna, and Glaser, Adam W

Published
2019
Full Text
View/download PDF

11. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

Author

Eden, Michael, Harrison, Samantha, Griffin, Michelle, Lambe, Mats, Pettersson, David, Gavin, Anna, Brewster, David H., Lin, Yulan, Johannesen, Tom B., Milne, Roger L., Farrugia, Helen, Nishri, Diane, King, Mary-Jane, Huws, Dyfed W, Warlow, Janet, Turner, Donna, Earle, Craig C., Peake, Michael, and Rashbass, Jem

Published
2019
Full Text
View/download PDF

14. Inequalities in colorectal cancer screening uptake in Wales: an examination of the impact of the temporary suspension of the screening programme during the COVID-19 pandemic

Author

Bright, Diana, primary, Hillier, Sharon, additional, Song, Jiao, additional, Huws, Dyfed W., additional, Greene, Giles, additional, Hodgson, Karen, additional, Akbari, Ashley, additional, Griffiths, Rowena, additional, Davies, Alisha R., additional, and Gjini, Ardiana, additional

Published
2022
Full Text
View/download PDF

15. International variation in oesophageal and gastric cancer survival 2012-2014:differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)

Author

Arnold, Melina, Morgan, Eileen, Bardot, Aude, Rutherford, Mark J., Ferlay, Jacques, Little, Alana, Møller, Bjorn, Bucher, Oliver, De, Prithwish, Woods, Ryan R., Saint-Jacques, Nathalie, Gavin, Anna T., Engholm, Gerda, Achiam, Michael P., Porter, Geoff, Walsh, Paul M., Vernon, Sally, Kozie, Serena, Ramanakumar, Agnihotram V., Lynch, Charlotte, Harrison, Samantha, Merrett, Neil, O'Connell, Dianne L., Mala, Tom, Elwood, Mark, Zalcberg, John, Huws, Dyfed W., Ransom, David, Bray, Freddie, Soerjomataram, Isabelle, Arnold, Melina, Morgan, Eileen, Bardot, Aude, Rutherford, Mark J., Ferlay, Jacques, Little, Alana, Møller, Bjorn, Bucher, Oliver, De, Prithwish, Woods, Ryan R., Saint-Jacques, Nathalie, Gavin, Anna T., Engholm, Gerda, Achiam, Michael P., Porter, Geoff, Walsh, Paul M., Vernon, Sally, Kozie, Serena, Ramanakumar, Agnihotram V., Lynch, Charlotte, Harrison, Samantha, Merrett, Neil, O'Connell, Dianne L., Mala, Tom, Elwood, Mark, Zalcberg, John, Huws, Dyfed W., Ransom, David, Bray, Freddie, and Soerjomataram, Isabelle

Abstract

OBJECTIVE: To provide the first international comparison of oesophageal and gastric cancer survival by stage at diagnosis and histological subtype across high-income countries with similar access to healthcare. METHODS: As part of the ICBP SURVMARK-2 project, data from 28 923 patients with oesophageal cancer and 25 946 patients with gastric cancer diagnosed during 2012-2014 from 14 cancer registries in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK) were included. 1-year and 3-year age-standardised net survival were estimated by stage at diagnosis, histological subtype (oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC)) and country. RESULTS: Oesophageal cancer survival was highest in Ireland and lowest in Canada at 1 (50.3% vs 41.3%, respectively) and 3 years (27.0% vs 19.2%) postdiagnosis. Survival from gastric cancer was highest in Australia and lowest in the UK, for both 1-year (55.2% vs 44.8%, respectively) and 3-year survival (33.7% vs 22.3%). Most patients with oesophageal and gastric cancer had regional or distant disease, with proportions ranging between 56% and 90% across countries. Stage-specific analyses showed that variation between countries was greatest for localised disease, where survival ranged between 66.6% in Australia and 83.2% in the UK for oesophageal cancer and between 75.5% in Australia and 94.3% in New Zealand for gastric cancer at 1-year postdiagnosis. While survival for OAC was generally higher than that for OSCC, disparities across countries were similar for both histological subtypes. CONCLUSION: Survival from oesophageal and gastric cancer varies across high-income countries including within stage groups, particularly for localised disease. Disparities can partly be explained by earlier diagnosis resulting in more favourable stage distributions, and distributions of histological subtypes of oesophageal cancer across countries. Yet, differences in treatment, and also

Published
2022

16. Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study

Author

McPhail, Sean, primary, Swann, Ruth, additional, Johnson, Shane A, additional, Barclay, Matthew E, additional, Abd Elkader, Hazem, additional, Alvi, Riaz, additional, Barisic, Andriana, additional, Bucher, Oliver, additional, Clark, Gavin R C, additional, Creighton, Nicola, additional, Danckert, Bolette, additional, Denny, Cheryl A, additional, Donnelly, David W, additional, Dowden, Jeff J, additional, Finn, Norah, additional, Fox, Colin R, additional, Fung, Sharon, additional, Gavin, Anna T, additional, Gomez Navas, Elba, additional, Habbous, Steven, additional, Han, Jihee, additional, Huws, Dyfed W, additional, Jackson, Christopher G C A, additional, Jensen, Henry, additional, Kaposhi, Bethany, additional, Kumar, S Eshwar, additional, Little, Alana L, additional, Lu, Shuang, additional, McClure, Carol A, additional, Møller, Bjørn, additional, Musto, Grace, additional, Nilssen, Yngvar, additional, Saint-Jacques, Nathalie, additional, Sarker, Sabuj, additional, te Marvelde, Luc, additional, Thomas, Rebecca S, additional, Thomas, Robert J S, additional, Thomson, Catherine S, additional, Woods, Ryan R, additional, Zhang, Bin, additional, Lyratzopoulos, Georgios, additional, Filsinger, Brooke, additional, Forster, Katharina, additional, May, Leon, additional, Morrison, David S, additional, Thomas, A. Ffion, additional, Warlow, Janet L, additional, and You, Hui, additional

Published
2022
Full Text
View/download PDF

17. International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)

Author

Arnold, Melina, primary, Morgan, Eileen, additional, Bardot, Aude, additional, Rutherford, Mark J, additional, Ferlay, Jacques, additional, Little, Alana, additional, Møller, Bjorn, additional, Bucher, Oliver, additional, De, Prithwish, additional, Woods, Ryan R, additional, Saint-Jacques, Nathalie, additional, Gavin, Anna T, additional, Engholm, Gerda, additional, Achiam, Michael P, additional, Porter, Geoff, additional, Walsh, Paul M, additional, Vernon, Sally, additional, Kozie, Serena, additional, Ramanakumar, Agnihotram V, additional, Lynch, Charlotte, additional, Harrison, Samantha, additional, Merrett, Neil, additional, O’Connell, Dianne L, additional, Mala, Tom, additional, Elwood, Mark, additional, Zalcberg, John, additional, Huws, Dyfed W, additional, Ransom, David, additional, Bray, Freddie, additional, and Soerjomataram, Isabelle, additional

Published
2021
Full Text
View/download PDF

18. Impact of case management by advanced practice nurses in primary care on unplanned hospital admissions: a controlled intervention study

Author

Vincent Judith, Roberts Catherine, Newcombe Robert G, Cashmore Deborah, Huws Dyfed W, and Elwyn Glyn

Subjects
Public aspects of medicine, RA1-1270
Abstract

Abstract Background Increasing unplanned hospital admissions disrupt planned health care, lead to additional morbidity and are expensive. A recent review found only weak evidence for case management preventing unplanned admissions, yet case management of older people is being implemented widely in the UK. We aimed to study the effect of advanced practice nurse case management on unplanned medical and geriatric hospital admission rates in patients 50 years and over, and on admission risk in a 'higher risk' sub-group of patients in the UK. Methods Case management by advanced practice nurses in NHS primary care practices in the Swansea Local Health Board area, Wales, UK. We conducted a prospective non-randomized controlled intervention study comparing unplanned medical and geriatric patient admissions between five intervention and thirty non-intervention practices during a pre-intervention year and an intervention year. Results For all lengths of stay, comparing intervention (n = 5) with non-intervention practices (n = 30) from pre-intervention to intervention year, we found that the unplanned medical and geriatric admission rate was significantly lower in the intervention group – adjusted relative risk of 0.909; relative risk reduction 9.1% (95% credible limit 0.840 to 0.984, p = 0.018); absolute risk reduction 0.99 admissions per 100 patients (95% credible limit 0.17 to 1.86, p = 0.018). For lengths of stay of one night or more we observed a stronger effect – adjusted relative risk 0.896; relative risk reduction 10.41% (95%, credible limit 0.820 to 0.979, p = 0.015). Most of the rate reduction was due to a reduction in the number of new admissions but much less so for admissions of lengths of stay of at least one night, compared to all lengths of stay. We did not find a statistically significant effect on re-admission or multiple re-admission rates in 'higher risk' patients previously admitted one or more times – adjusted relative risk of further multiple admissions per previously admitted patient 0.908 (95% credible limit 0.765, 1.077); relative risk reduction 9.3%; adjusted relative risk of total admissions per multiple admitter 0.995 (95% credible limit 0.940, 1.053) relative risk reduction 0.6%. Conclusion Although this study reports a reduction in unplanned admission rates in the intervention practices, this appears to be only in part directly due to nurse case management: most of the reduction did not occur in multipe admitters whom were case managed. Further research is needed to explain this finding, to elucidate how best to target the attention of case managers and to examine the complexity of potential outcomes in terms of the nature and necessity of admissions and most suitable lengths-of-stay in terms of acute care or rehabilittion need.

Published
2008
Full Text
View/download PDF

19. Quality of life in men living with advanced and localised prostate cancer: A United Kingdom population-wide patient-reported outcome study of 30,000 men

Author

Downing, Amy, Wright, Penny, Hounsome, Luke, Selby, Peter, Wilding, Sarah, Watson, Eila, Wagland, Richard, Kind, Paul, Donnelly, David W., Butcher, Hugh, Catto, James W.F., Cross, William, Mason, Malcolm, Sharp, Linda, Weller, David, Velikova, Galina, McCaughan, Eilis, Mottram, Rebecca, Allen, Majorie, Kearney, Therese, McSorley, Oonagh, Huws, Dyfed W., Brewster, David H., McNair, Emma, Gavin, Anna, Glaser, Adam W., Downing, Amy, Wright, Penny, Hounsome, Luke, Selby, Peter, Wilding, Sarah, Watson, Eila, Wagland, Richard, Kind, Paul, Donnelly, David W., Butcher, Hugh, Catto, James W.F., Cross, William, Mason, Malcolm, Sharp, Linda, Weller, David, Velikova, Galina, McCaughan, Eilis, Mottram, Rebecca, Allen, Majorie, Kearney, Therese, McSorley, Oonagh, Huws, Dyfed W., Brewster, David H., McNair, Emma, Gavin, Anna, and Glaser, Adam W.

Abstract

Background. Little is known about the health-related quality of life (HRQL) of men living with advanced prostate cancer. We report population-wide functional outcomes and HRQL in men with all stages of prostate cancer, and identify implications for healthcare delivery. Methods. Men alive 18-42 months after diagnosis of prostate cancer were identified through cancer registration data. A postal survey was administered which contained validated measures to assess a) functional outcomes (EPIC-26 plus use of interventions for sexual dysfunction) and b) generic HRQL (EQ-5D-5L & self-assessed health). Log-linear and binary logistic regression models were used to compare functional outcomes and HRQL across diagnostic stage and self-reported treatment groups. Findings. 35,823 (60.8%) men responded. Stage was known for 85.8%; 19,599 (63.8%) stage I/II, 7,209 (23.4%) stage III, 3,925 (12.8%) stage IV. Functional outcomes: Poor sexual function was common (81.0%), regardless of stage, and over half of men (55.8%) received no intervention for this. Differences in urinary and bowel morbidity were greater with respect to treatment than stage. In men treated with androgen deprivation therapy (ADT), 30.7% reported moderate/big problems with hot flushes, 29.4% with lack of energy and 22.5% with weight gain. HRQL: Overall self-assessed health was similar in men with stage I-III disease, and whilst reduced in those with stage IV cancer, 23.5% with metastatic disease reported no problems on any EQ-5D dimension. Interpretation. Men diagnosed with advanced disease do not report markedly different HRQL outcomes to those diagnosed with localised disease, although substantial problems with hormonal function and fatigue are reported amongst men treated with ADT. Sexual dysfunction is common and the majority of men are not offered helpful intervention or support. Service improvements around sexual rehabilitation and measures to reduce the impact of ADT are required.

Published
2019

20. International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)

Author

Arnold, Melina, Morgan, Eileen, Bardot, Aude, Rutherford, Mark J, Ferlay, Jacques, Little, Alana, Møller, Bjorn, Bucher, Oliver, De, Prithwish, Woods, Ryan R, Saint-Jacques, Nathalie, Gavin, Anna T, Engholm, Gerda, Achiam, Michael P, Porter, Geoff, Walsh, Paul M, Vernon, Sally, Kozie, Serena, Ramanakumar, Agnihotram V, Lynch, Charlotte, Harrison, Samantha, Merrett, Neil, O’Connell, Dianne L, Mala, Tom, Elwood, Mark, Zalcberg, John, Huws, Dyfed W, Ransom, David, Bray, Freddie, and Soerjomataram, Isabelle

Abstract

ObjectiveTo provide the first international comparison of oesophageal and gastric cancer survival by stage at diagnosis and histological subtype across high-income countries with similar access to healthcare.MethodsAs part of the ICBP SURVMARK-2 project, data from 28 923 patients with oesophageal cancer and 25 946 patients with gastric cancer diagnosed during 2012–2014 from 14 cancer registries in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK) were included. 1-year and 3-year age-standardised net survival were estimated by stage at diagnosis, histological subtype (oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC)) and country.ResultsOesophageal cancer survival was highest in Ireland and lowest in Canada at 1 (50.3% vs 41.3%, respectively) and 3 years (27.0% vs 19.2%) postdiagnosis. Survival from gastric cancer was highest in Australia and lowest in the UK, for both 1-year (55.2% vs 44.8%, respectively) and 3-year survival (33.7% vs 22.3%). Most patients with oesophageal and gastric cancer had regional or distant disease, with proportions ranging between 56% and 90% across countries. Stage-specific analyses showed that variation between countries was greatest for localised disease, where survival ranged between 66.6% in Australia and 83.2% in the UK for oesophageal cancer and between 75.5% in Australia and 94.3% in New Zealand for gastric cancer at 1-year postdiagnosis. While survival for OAC was generally higher than that for OSCC, disparities across countries were similar for both histological subtypes.ConclusionSurvival from oesophageal and gastric cancer varies across high-income countries including within stage groups, particularly for localised disease. Disparities can partly be explained by earlier diagnosis resulting in more favourable stage distributions, and distributions of histological subtypes of oesophageal cancer across countries. Yet, differences in treatment, and also in cancer registration practice and the use of different staging methods and systems, across countries may have impacted the comparisons. While primary prevention remains key, advancements in early detection research are promising and will likely allow for additional risk stratification and survival improvements in the future.

Published
2022
Full Text
View/download PDF

21. Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer

Author

Lüchtenborg, Margreet, primary, Morris, Eva J A, additional, Tataru, Daniela, additional, Coupland, Victoria H, additional, Smith, Andrew, additional, Milne, Roger L, additional, te Marvelde, Luc, additional, Baker, Deborah, additional, Young, Jane, additional, Turner, Donna, additional, Nishri, Diane, additional, Earle, Craig, additional, Shack, Lorraine, additional, Gavin, Anna, additional, Fitzpatrick, Deirdre, additional, Donnelly, Conan, additional, Lin, Yulan, additional, Møller, Bjørn, additional, Brewster, David H, additional, Deas, Andrew, additional, Huws, Dyfed W, additional, White, Ceri, additional, Warlow, Janet, additional, Rashbass, Jem, additional, and Peake, Michael D, additional

Published
2017
Full Text
View/download PDF

22. Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer

Author

Luchtenborg, Margreet, Morris, Eva J A, Tataru, Daniela, Coupland, Victoria H, Smith, Andrew, Milne, Roger L, te Marvelde, Luc, Baker, Deborah, Young, Jane, Turner, Donna, Nishri, Diane, Earle, Craig, Shack, Lorraine, Gavin, Anna, Fitzpatrick, Deirdre, Donnelly, Conan, Lin, Yulan, Møller, Bjørn, Brewster, David H, Deas, Andrew, Huws, Dyfed W, White, Ceri, Warlow, Janet, Rashbass, Jem, and Peake, Michael D

Abstract

IntroductionThe International Cancer Benchmarking Partnership (ICBP) identified significant international differences in lung cancer survival. Differing levels of comorbid disease across ICBP countries has been suggested as a potential explanation of this variation but, to date, no studies have quantified its impact. This study investigated whether comparable, robust comorbidity scores can be derived from the different routine population-based cancer data sets available in the ICBP jurisdictions and, if so, use them to quantify international variation in comorbidity and determine its influence on outcome.MethodsLinked population-based lung cancer registry and hospital discharge data sets were acquired from nine ICBP jurisdictions in Australia, Canada, Norway and the UK providing a study population of 233 981 individuals. For each person in this cohort Charlson, Elixhauser and inpatient bed day Comorbidity Scores were derived relating to the 4–36 months prior to their lung cancer diagnosis. The scores were then compared to assess their validity and feasibility of use in international survival comparisons.ResultsIt was feasible to generate the three comorbidity scores for each jurisdiction, which were found to have good content, face and concurrent validity. Predictive validity was limited and there was evidence that the reliability was questionable.ConclusionThe results presented here indicate that interjurisdictional comparability of recorded comorbidity was limited due to probable differences in coding and hospital admission practices in each area. Before the contribution of comorbidity on international differences in cancer survival can be investigated an internationally harmonised comorbidity index is required.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results